MediXall Group Statistics
Total Valuation
MediXall Group has a market cap or net worth of 851,904. The enterprise value is 4.68 million.
| Market Cap | 851,904 |
| Enterprise Value | 4.68M |
Important Dates
The last earnings date was Friday, May 30, 2025.
| Earnings Date | May 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MediXall Group has 218.44 million shares outstanding.
| Current Share Class | 218.44M |
| Shares Outstanding | 218.44M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +3.57% |
| Owned by Insiders (%) | 2.30% |
| Owned by Institutions (%) | 3.84% |
| Float | 187.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.57 |
| PB Ratio | -0.11 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.28 |
| EV / Sales | 14.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.01
| Current Ratio | 0.01 |
| Quick Ratio | 0.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.18 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -439.75% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 34.04% |
| Revenue Per Employee | 47,288 |
| Profits Per Employee | -521,323 |
| Employee Count | 7 |
| Asset Turnover | 0.92 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +389,900.00% in the last 52 weeks. The beta is 40.56, so MediXall Group's price volatility has been higher than the market average.
| Beta (5Y) | 40.56 |
| 52-Week Price Change | +389,900.00% |
| 50-Day Moving Average | 0.34 |
| 200-Day Moving Average | 1.09 |
| Relative Strength Index (RSI) | 41.08 |
| Average Volume (20 Days) | 10,691 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MediXall Group had revenue of 331,013 and -3.65 million in losses. Loss per share was -0.04.
| Revenue | 331,013 |
| Gross Profit | -698,794 |
| Operating Income | -2.54M |
| Pretax Income | -3.33M |
| Net Income | -3.65M |
| EBITDA | -2.51M |
| EBIT | -2.54M |
| Loss Per Share | -0.04 |
Balance Sheet
The company has 32,621 in cash and 423,392 in debt, giving a net cash position of -390,771 or -0.00 per share.
| Cash & Cash Equivalents | 32,621 |
| Total Debt | 423,392 |
| Net Cash | -390,771 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -7.50M |
| Book Value Per Share | -0.05 |
| Working Capital | -7.64M |
Cash Flow
| Operating Cash Flow | -1.07M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | -211.11% |
| Operating Margin | -766.22% |
| Pretax Margin | -1,007.51% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MediXall Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.67% |
| Shareholder Yield | n/a |
| Earnings Yield | -428.37% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MediXall Group has an Altman Z-Score of -307.89 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -307.89 |
| Piotroski F-Score | 4 |